Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments

Virpax® Pharmaceuticals, Inc. , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and viral... | May 12, 2023

Related Keywords

Lawrence Fried ,Kenneth Sommerville ,Barbaraa Ruskin ,Pardeep Gupta ,Kennethw Sommerville ,Virpax Envelta ,Anthonyp Mack ,Pharmaceuticals Inc ,Company Anqlar ,Harvard University ,England Investors ,Molecular Envelope Technology ,Translational Sciences ,Securities Exchange ,Exchange Commission ,Destum Partners Inc ,Virpax Pharmaceuticals ,Nasdaq ,National Center ,Linkedin ,National Institutes Of Health ,Twitter ,Youtube ,Department Of Defense ,Chief Executive Officer ,Neil Singla ,Advancing Translational Sciences ,Investigational New Drug ,New England Investors ,Destum Partners ,Tech Watch Seminar ,National Institutes ,Molecular Biology ,Chief Intellectual Property ,Innovation Officer ,Silence Therapeutics ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Three Months Ended March ,Nc Stock Exchange ,News ,Information ,Press Release ,Company ,Pecializing ,N ,Developing ,Products ,Or ,Rain ,Stress ,Central ,Nervous ,System ,Disorders ,Nd Vrpx Us9282511073 ,